Jiuzhitang Co., Ltd. (000989.SZ)
- Previous Close
9.04 - Open
8.57 - Bid 9.18 x --
- Ask 9.19 x --
- Day's Range
9.01 - 9.22 - 52 Week Range
6.10 - 9.22 - Volume
16,168,659 - Avg. Volume
11,207,531 - Market Cap (intraday)
7.875B - Beta (5Y Monthly) --
- PE Ratio (TTM)
41.82 - EPS (TTM)
0.22 - Earnings Date --
- Forward Dividend & Yield 0.40 (4.42%)
- Ex-Dividend Date May 28, 2024
- 1y Target Est
--
Jiuzhitang Co., Ltd. provides traditional Chinese, chemical, biological, and health medicine products in China. The company offers Shuxuetong injections, Angong Niuhuang pills, Gastrodia Gouteng granules, Danxi granules, and Compound Jiangzhi tablets for cardiovascular and neurological treatment; Nudehua Zizhu tablets, Xiaojin pills, Guizhi Fuling pills, Buxue Shengru granules, and Zhixue Analgesic capsules for the treatment in gynecology; Houyan pills for ear, nose, and throat (ENT) diseases; Jianwei Yuyang tablets for digestion; and prescription drug product systems, Jiaqi Ganxian granules, and Chidan Tuihuang granules for liver diseases. It also provides over the counter (OTC) drugs comprising blood-tonifying, cardiovascular and cerebrovascular, urinary system, pediatric, gynecologic, bone and muscles, respiratory system, dermatologic, nervous system, ENT, and digestive system products; and stem cell and other drugs. Jiuzhitang Co., Ltd. was founded in 1999 and is headquartered in Beijing, China.
www.hnjzt.com--
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: 000989.SZ
View MorePerformance Overview: 000989.SZ
Trailing total returns as of 4/25/2025, which may include dividends or other distributions. Benchmark is SSE Composite Index (000001.SS) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 000989.SZ
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 000989.SZ
View MoreValuation Measures
Market Cap
7.74B
Enterprise Value
6.84B
Trailing P/E
40.52
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.65
Price/Book (mrq)
2.00
Enterprise Value/Revenue
3.26
Enterprise Value/EBITDA
30.13
Financial Highlights
Profitability and Income Statement
Profit Margin
8.97%
Return on Assets (ttm)
2.09%
Return on Equity (ttm)
4.72%
Revenue (ttm)
2.1B
Net Income Avi to Common (ttm)
188.15M
Diluted EPS (ttm)
0.22
Balance Sheet and Cash Flow
Total Cash (mrq)
945.22M
Total Debt/Equity (mrq)
1.09%
Levered Free Cash Flow (ttm)
530.43M